Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Earnings Beat

Trevi Therapeutics, Inc. (NASDAQ:TRVI)’s share price gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $11.19, but opened at $11.86. Trevi Therapeutics shares last traded at $10.8890, with a volume of 178,855 shares traded.

The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04.

Key Stories Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Morgan Stanley reduced their price objective on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $21.33.

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently modified their holdings of TRVI. Hilton Head Capital Partners LLC purchased a new position in Trevi Therapeutics during the 4th quarter valued at about $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Trevi Therapeutics in the 4th quarter worth approximately $50,000. Russell Investments Group Ltd. lifted its holdings in Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after buying an additional 1,523 shares during the last quarter. Finally, BIT Capital GmbH grew its position in shares of Trevi Therapeutics by 32.0% in the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock worth $62,000 after buying an additional 1,633 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Price Performance

The stock has a market capitalization of $1.37 billion, a PE ratio of -33.41 and a beta of 0.94. The company has a 50 day moving average price of $11.15 and a 200-day moving average price of $10.93.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.